[A study of the clinical usefulness of the CA15-3 radioimmunoassay kit].
We have studied the clinical usefulness of the CA15-3 radioimmunoassay (RIA) kit that has been developed with two monoclonal antibodies (115D 8 and DF 3). Serum levels of CA15-3 exceeding the normal level were found in a high percentage of patients with ovarian cancer (80%), lung cancer (62.5%) and breast cancer (29.3%). In patients with breast cancer, the mean concentrations of CA15-3 before operation were higher than those after operation. Further, the levels of CA15-3 showed a good correlation with the extent and the stage of the breast cancer. These results suggest that CA15-3 levels can provide monitoring information in the follow-up management of patients with breast cancer.
Abe
Y
Y
Radioassay Center, Tokyo Women's Medical College.
Odagiri
E
E
Jibiki
K
K
Demura
R
R
Demura
H
H
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D001943:Breast Neoplasms / Q000276:immunology; D005260:Female; D008175:Lung Neoplasms / Q000276:immunology; D008297:Male; D009369:Neoplasms / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000276:immunology; D011863:Radioimmunoassay; D011933:Reagent Kits, Diagnostic
D015295:Antigens, Tumor-Associated, Carbohydrate; D011933:Reagent Kits, Diagnostic